As of the latest Form 4 filed Jul 9, 2026.
What Immunome Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 28 most recent filings for IMNM.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | Horn Kinney CHIEF BUSINESS OFFICER | SSale | −1.09K | $25.00 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | Horn Kinney, CHIEF BUSINESS OFFICER | MExercise | +1.09K | $12.92 | $14.1K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-07 | Barchas Isaac Director | SSale | −16.9K | $24.20 | $409K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-06 | Barchas Isaac, Director | SSale | −83.1K | $24.11 | $2.00M | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Lechleider Robert Chief Medical Officer | SSale | −16.1K | $23.44 | $377K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Lechleider Robert, Chief Medical Officer | SSale | −16.2K | $22.76 | $369K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Lechleider Robert, Chief Medical Officer | SSale | −22.7K | $21.95 | $499K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Lechleider Robert, Chief Medical Officer | MExercise | +55.0K | $8.73 | $480K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-02 | Barchas Isaac Director | SSale | −24.3K | $23.33 | $568K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-02 | Barchas Isaac, Director | SSale | −75.7K | $22.35 | $1.69M | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Barchas Isaac, Director | SSale | −101K | $21.12 | $2.13M | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Lechleider Robert Chief Medical Officer | SSale | −14.4K | $20.66 | $298K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Lechleider Robert, Chief Medical Officer | SSale | −40.6K | $19.56 | $794K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Lechleider Robert, Chief Medical Officer | MExercise | +55.0K | $8.73 | $480K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Rosett Max Chief Financial Officer | SSale | −60.0K | $18.23 | $1.09M | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Rosett Max, Chief Financial Officer | MExercise | +60.0K | $1.05 | $63.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BIENAIME JEAN JACQUES Director | PPurchase | +1.00K | $19.27 | $19.3K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BIENAIME JEAN JACQUES, Director | PPurchase | +3.50K | $19.46 | $68.1K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BIENAIME JEAN JACQUES, Director | PPurchase | +6.00K | $19.48 | $117K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BIENAIME JEAN JACQUES, Director | SSale | −10.0K | $19.41 | $194K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | BIENAIME JEAN JACQUES, Director | SSale | −500.00 | $19.44 | $9.72K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | BIENAIME JEAN JACQUES Director | PPurchase | +5.00K | $20.70 | $104K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Higgins Jack Chief Scientific Officer | GGift | −6.29K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-27 | SIEGALL CLAY B President and CEO | PPurchase | +25.4K | $19.67 | $501K | No | Form 4 ↗ |
| 2026-03-23 | 2026-03-23 | WAGENHEIM PHILIP Director | SSale | −28.2K | $20.65 | $582K | No | Form 4 ↗ |
| 2026-03-23 | 2026-03-20 | WAGENHEIM PHILIP, Director | SSale | −36.8K | $20.47 | $753K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-11 | BIENAIME JEAN JACQUES Director | PPurchase | +1.00K | $21.55 | $21.6K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | BIENAIME JEAN JACQUES, Director | PPurchase | +1.00K | $22.12 | $22.1K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IMNM’s full analysis or the market-wide insider trading feed. The tabs above jump to IMNM’s other SEC data.
Source: SEC Form 4 filings for IMNM, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.